Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xentuzumab plus Afatinib in EGFR-mutant NSCLC
NCT02191891Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2014
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of xentuzumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Oct 2014; status: completed.
02
Drugs
xentuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02191891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191891.